TITLE:
Registry of Etanercept (Enbrel) In Children With Juvenile Rheumatoid Arthritis

CONDITION:
Juvenile Rheumatoid Arthritis

INTERVENTION:
Enbrel

SUMMARY:

      This study will evaluate long-term safety of etanercept with or without other DMARDs in
      children with polyarticular course or systemic juvenile rheumatoid arthritis (JRA) compared
      to a cohort of subjects with polyarticular or systemic JRA receiving methotrexate with or
      without other DMARDs.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 2 Years to 18 Years
Criteria:

        -  JRA by American College of Rheumatology (ACR) criteria - Active joints - Initiate
             etanercept alone, etanercept plus methotrexate or other DMARDs, methotrexate alone,
             or methotrexate with other DMARDs within 6 months of entry into Registry

          -  Polyarticular or systemic RA in 3 or more joints at start of treatment
      
